A Phase 2 Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VSN16R for the treatment of spasticity in patients with Multiple Sclerosis (MS)

Trial Profile

A Phase 2 Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VSN16R for the treatment of spasticity in patients with Multiple Sclerosis (MS)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs VSN 16R (Primary)
  • Indications Muscle spasticity
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Canbex Therapeutics
  • Most Recent Events

    • 30 Jan 2017 Planned End Date changed from 1 Oct 2016 to 1 Dec 2017.
    • 30 Jan 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Aug 2017.
    • 02 Nov 2015 Top-line results are expected to be available in 2016, according to a Canbex Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top